7th November 2016
Innovative biotechnology company, Axim Biotechnologies Inc has appointed Grayling in the US to support its Investor Relations and Public Relations’ needs.
Axim Biotechnologies is engaged in the research and development, and production of pharmaceutical, nutriceutical and cosmetic products, as well as the procurement of genetically and nano-controlled active ingredients. The company’s particular focus is on the development of treatments for pain, spasticity, anxiety and other medical disorders using cannabinoids-based products. Pharmaceutical R&D aims to deliver systems and active pharmaceutical ingredients for treating conditions such as Parkinson's disease, Alzheimer's disease, restless leg syndrome and Crohn's disease.
Presently, the company is conducting clinical studies of MedChewRx, a pharmaceutical chewing gum containing cannabinoids. The company is in the process of getting FDA and EMA regulatory approval to launch this product in 2017, and it is in regard to this that Grayling is providing support.
Grayling’s efforts will be driven by New York based executive vice president, Lucia Domville. She says: “This is a fascinating company that is really pushing the boundaries with its research, and we are thrilled to be their partner.”
28th November 2018
Independent ratings agency, Weiss Ratings, has hired Grayling in the US to help solidify its leadership position in the field of cryptocurrency ratings. Weiss Cryptocurrency Ratings were...Read More
26th November 2018
The Prizma Kreatív PR Awards are the most prestigious in the Hungarian PR industry, and at the annual ceremony last week, Grayling’s team in Budapest received a bronze award for developing and...Read More
22nd November 2018
Grayling Brussels has won the Brexit-related Campaign of the Year Award at the prestigious Public Affairs Awards Europe. The Grayling Brexit Unit, set up in January 2016, provides clients across all...Read More